What Xenon Pharmaceuticals Inc. told the SEC could break it.

Xenon owns no manufacturing or testing facilities and lacks the capability to build them, so it relies entirely on third parties to manufacture and supply the active pharmaceutical ingredients (APIs) and final drug-product formulation for all of its product candidates (including lead candidate azetukalner), plus packaging and labeling, across pre-clinical, clinical and any future commercial supply. CMO capacity, quality, timing or pricing problems could delay its epilepsy programs.

“We do not own or operate manufacturing or testing facilities for the production of clinical or commercial quantities of our product candidates, and we lack the resources and the capabilities to do so. As a result, we currently rely on third parties for the manufacture and supply of the active pharmaceutical ingredients, or APIs, in our product candidates and the final drug product formulation for all of our product candidates that are being used in our clinical studies and pre-clinical studies as well as packaging, labell”

As a Burnaby, BC-headquartered company that develops and (via CMOs) manufactures its product candidates outside the United States, Xenon is exposed to escalating trade policy: tariffs already imposed on certain goods, reciprocal tariffs imposed by Canada and other countries where it does business, and potential tariffs the administration has contemplated specifically on pharmaceutical products and components manufactured outside the U.S. Combined with US-Canada trade tensions affecting its Canadian-dollar cost base, these could raise its development and (future) commercial supply costs.

“changes in tariffs, trade barriers and regulatory requirements, including tariffs that have been imposed on certain goods by the current presidential administration and reciprocal tariffs imposed by Canada and other countries in which we do business, as well as potential tariffs on pharmaceutical products and components manufactured outside the United States that the current presidential administration has contemplated”